Liberalised German market "to provide spur for medtech"
This article was originally published in Clinica
BVMed industry association chairman Anton Schmidt (Johnson & Johnson) believes that a deregulated and liberalised healthcare market, with bureaucracy cut away, would provide optimum conditions for the introduction of more medical technology innovations.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.